Phoenix Molecular Designs Receives FDA Clearance to Begin Phase 1/1b Clinical Trial with PMD-026, a First-in-Class RSK Inhibitor, Targeting Advanced Breast Cancer
/Sep. 23
2019
SAN DIEGO, and VANCOUVER, British Columbia, Sept. 23, 2019 - PhoenixMD received clearance from the Food and Drug Administration (FDA) for their Investigational New Drug (IND) application for its proprietary PMD-026. That clearance permits PhoenixMD to begin patient enrollment into its Phase 1/1b clinical trial, which is expected to start in the United States during the fourth quarter of 2019.
Read the story here